Novartis’s T-Charge Platform Reduces CAR-T Manufacturing to 2 Days; Novartis’s R&D Day Summary
On Thursday, December 2, Novartis held their R&D day (press release / presentation) highlighting T-Charge, a next-generation CAR-T manufacturing platform that reduces manufacturing time to ~2 days. Moreover, management discussed two novel assets YTB323 (CD19 CAR-T) and PHE885 (BCMA CAR-T) manufactured using the T-Charge platform. Below, Celltelligence provides insights on how Novartis could leverage T-Charge’s rapid manufacturing and potentially lower COGS to position their novel assets within the already crowded DLBCL and MM settings.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.